Skip to main content
main-content

Medicine Matters rheumatology

Featured research: Online self-management for JIA

09-11-2017 | ACR/ARHP 2017 | Video

Internet-based educational tool improves juvenile idiopathic arthritis QoL

Study investigator Jennifer Stinson discusses a trial assessing an online program to help teenagers with juvenile idiopathic arthritis to manage their condition.

17-11-2017 | Juvenile idiopathic arthritis | ACR/ARHP 2017 | News

Online self-management program boosts JIA HRQoL

An internet-based educational tool developed by Canadian researchers helps adolescents with juvenile idiopathic arthritis to manage their disease and leads to improvements in their health-related quality of life relative to standard disease education.

09-11-2017 | ACR/ARHP 2017 | Video

Expert commentary: Tapping into technology to manage juvenile idiopathic arthritis

Editorial Board member Sangeeta Sule discusses a trial of an online self-management tool for adolescents with juvenile idiopathic arthritis, and the role of technology and education to manage the condition.

Featured research: Biologic treatment during pregnancy and infection risk in infants

07-11-2017 | ACR/ARHP 2017 | Video

Biologic use during pregnancy poses no serious infection risk in infants

Lead author Christina Chambers outlines the findings of an investigation into the effects of biologic therapy in pregnant women with rheumatoid arthritis on the risk for opportunistic infections in the babies.

07-11-2017 | Rheumatoid arthritis | ACR/ARHP 2017 | News

Infant serious infection reassurance for biologic use during pregnancy

The use of biologic agents by women with rheumatoid arthritis during pregnancy is not associated with a raised risk for serious or opportunistic infections for their infants, suggests research reported at the 2017 ACR/ARHP Annual Meeting in San Diego, California, USA.

09-11-2017 | ACR/ARHP 2017 | Video

Expert commentary: Biologic use during pregnancy and infection risk in infants

Bonnie Bermas provides an independent viewpoint on the results of a study suggesting that the use of biologic agents by women with rheumatoid arthritis during pregnancy is not associated with an increased serious infection risk for their babies.

Expert interviews

08-11-2017 | ACR/ARHP 2017 | Video

Expert commentary: The ABILITY-3 trial

Walter Maksymowych comments on the ABILITY-3 trial results showing that continued adalimumab treatment is important for the maintenance of remission among patients with nonradiographic axial spondyloarthritis.

Read the accompanying news story

08-11-2017 | ACR/ARHP 2017 | Video

Expert commentary: Bisphosphonate drug holidays and fracture risk

Linda Russell gives an independent comment on a study showing that suspending bisphosphonate treatment for more than 2 years is associated with increased fracture risk.

Read the accompanying news story

07-11-2017 | ACR/ARHP 2017 | Video

The effects of obesity on the outcomes of rheumatic disorders

Margaret Tsai provides independent comment on three studies exploring the effects of obesity in patients with rheumatic diseases.

Research news

21-11-2017 | Juvenile idiopathic arthritis | ACR/ARHP 2017 | News

Tocilizumab promising in short and long term for severe JIA-associated uveitis

The anti-interleukin-6 receptor antibody tocilizumab improves ocular outcomes in the short and long term in patients with severe uveitis related to juvenile idiopathic arthritis, indicates research presented at the 2017 ACR/ARHP Annual Meeting in San Diego, California, USA.

20-11-2017 | Osteoarthritis | ACR/ARHP 2017 | News

Sprifermin shows potential as a disease-modifying OA treatment

Results of the phase II FORWARD trial suggest that sprifermin, an investigational recombinant human fibroblast growth factor, may prevent cartilage loss in patients with knee osteoarthritis, but its effect on pain and physical function remains unclear.

17-11-2017 | Juvenile idiopathic arthritis | ACR/ARHP 2017 | News

Online self-management program boosts JIA HRQoL

An internet-based educational tool developed by Canadian researchers helps adolescents with juvenile idiopathic arthritis to manage their disease and leads to improvements in their health-related quality of life relative to standard disease education.

Conference highlights

06-12-2017 | Obesity | Conference report | News

Obesity in rheumatic diseases: A modifiable target for improving outcomes?

Research presented at the 2017 ACR/ARHP Annual Meeting in San Diego, California, USA, highlighted the adverse effects of obesity on clinical and patient-reported outcomes in various rheumatic disorders, including axial spondyloarthropathy, systemic lupus erythematosus, and rheumatoid arthritis. In this report, we outline the main findings of four studies addressing this issue.

16-11-2017 | Rheumatoid arthritis | Conference report | News

Exploring RA treatment patterns

Several studies presented at the 2017 ACR/ARHP Annual Meeting in San Diego, California, USA, explored different aspects of rheumatoid arthritis treatment, including guideline recommendations, adherence to second-line therapy, and predicting treatment response.

13-11-2017 | Biosimilars | Conference report | News

‘The Great Debate’: Should rheumatologists prescribe biosimilars?

In the “Great Debate” session at the 2017 ACR/ARHP Annual Meeting in San Diego, California, USA, two experts discussed whether patients with rheumatic diseases who are treated with biologic DMARDs should switch to biosimilar agents, focusing on efficacy, safety, and cost.

image credits